UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent mice
  • Publication Type:
    Journal article
  • Publication Sub Type:
    JOUR
  • Authors:
    Waddington SN, Mitrophanous KA, Ellard F, Buckley SMK, Nivsarkar M, Lawrence L, Cook HT, Al-Allaf F, Bigger B, Kingsman S, Coutelle C, Themis M
  • Publication date:
    2003
  • Pagination:
    1234, 1240
  • Volume:
    10
  • Issue:
    15
  • Notes:
    Inefficient gene transfer, inaccessibility of stem cell compartments, transient gene expression and adverse immune and inflammatory reactions to vector and transgenic protein are major barriers to successful in vivo application of gene therapy for most genetic diseases. Prenatal gene therapy with integrating vectors may overcome these problems and prevent early irreparable organ damage. To this end high dose attenuated VSV-G pseudotyped equine infectious anaemia virus (EIAV) encoding ß-galactosidase under the CMV promoter was injected into the fetal circulation of immuno-competent MF1 mice. We saw prolonged, extensive gene expression in the liver, heart, brain, and muscle and to a lesser extent in the kidney and lung of postnatal mice. Progressive clustered hepatocyte staining suggests clonal expansion of cells stably transduced. We thus provide proof of principle for efficient gene delivery and persistent transgene expression after prenatal application of the EIAV vector and its potential for permanent correction of genetic diseases.
Abstract
Inefficient gene transfer, inaccessibility of stem cell compartments, transient gene expression and adverse immune and inflammatory reactions to vector and transgenic protein are major barriers to successful in vivo application of gene therapy for most genetic diseases. Prenatal gene therapy with integrating vectors may overcome these problems and prevent early irreparable organ damage. To this end high dose attenuated VSV-G pseudotyped equine infectious anaemia virus (EIAV) encoding ß-galactosidase under the CMV promoter was injected into the fetal circulation of immuno-competent MF1 mice. We saw prolonged, extensive gene expression in the liver, heart, brain, and muscle and to a lesser extent in the kidney and lung of postnatal mice. Progressive clustered hepatocyte staining suggests clonal expansion of cells stably transduced. We thus provide proof of principle for efficient gene delivery and persistent transgene expression after prenatal application of the EIAV vector and its potential for permanent correction of genetic diseases.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Author
Maternal & Fetal Medicine
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by